In addition to its [[prokinetic]] properties, mosapride also exerts anti-inflammatory effects on the gastrointestinal tract which may contribute to some of its therapeutic effects.<ref name="pmid21115544">{{cite journal  |vauthors=Tsuchida Y, Hatao F, Fujisawa M, etal |title=Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via α7nACh receptors on muscularis macrophages associated with postoperative ileus |journal=Gut |volume=60 |issue=5 |pages=638–47 |date=May 2011 |pmid=21115544 |pmc=3071096 |doi=10.1136/gut.2010.227546 |url=}}</ref> Mosapride also promotes [[neurogenesis]] in the gastrointestinal tract which may prove useful in certain bowel disorders.<ref name="pmid22194416">{{cite journal  |vauthors=Kawahara I, Kuniyasu H, Matsuyoshi H, etal |title=Comparison of effects of a selective 5-HT reuptake inhibitor versus a 5-HT4 receptor agonist on in vivo neurogenesis at the rectal anastomosis in rats |journal=Am. J. Physiol. Gastrointest. Liver Physiol. |volume=302 |issue=6 |pages=G588–97 |date=March 2012 |pmid=22194416 |doi=10.1152/ajpgi.00284.2011 |url=}}</ref><ref name="pmid20146727">{{cite journal  |vauthors=Matsuyoshi H, Kuniyasu H, Okumura M, etal |title=A 5-HT(4)-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult |journal=Neurogastroenterol. Motil. |volume=22 |issue=7 |pages=806–13, e226 |date=July 2010 |pmid=20146727 |doi=10.1111/j.1365-2982.2010.01474.x |url=}}</ref> The neurogenesis is due to mosapride's effect on the 5-HT<sub>4</sub> receptor where it acts as an agonist.<ref name="Goto-2013">{{Cite journal  | last1 = Goto | first1 = K. | last2 = Kato | first2 = G. | last3 = Kawahara | first3 = I. | last4 = Luo | first4 = Y. | last5 = Obata | first5 = K. | last6 = Misawa | first6 = H. | last7 = Ishikawa | first7 = T. | last8 = Kuniyasu | first8 = H. | last9 = Nabekura | first9 = J. | last10 = Takaki | first10 = M | title = In vivo imaging of enteric neurogenesis in the deep tissue of mouse small intestine. | journal = PLOS ONE | volume = 8 | issue = 1 | pages = e54814 | month =  | year = 2013 | doi = 10.1371/journal.pone.0054814 | PMID = 23382976 | pmc=3561410}}</ref>

 
Its common side effects include dry mouth, abdominal pain, dizziness, headache, insomnia, [[malaise]], nausea, diarrhea and sometimes constipation.<ref name="pmid18457463"/><ref>[http://www.drugsupdate.com/generic/view/328 Mosapride drug information - Drugs Update India<!-- Bot generated title -->]</ref> Unlike some other prokinetic agents, mosapride has little effect on potassium channels, no effect on [[hERG]] transfected cells, and no effect on cardiovascular function that could be detected in tests on humans.<ref name="Tack-2012"/><ref name="Kii-1997">{{Cite journal  | last1 = Kii | first1 = Y. | last2 = Ito | first2 = T. | title = Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles | journal = J Cardiovasc Pharmacol | volume = 29 | issue = 5 | pages = 670–5 |date=May 1997 | doi =  10.1097/00005344-199705000-00016| pmid = 9213211 }}</ref> Due to the pharmacokinetics of mosapride, it would take 1,000–3,000 times the therapeutic dose to elicit cardiovascular effects.<ref name="Kii-2002">{{Cite journal  | last1 = Kii | first1 = Y. | last2 = Ito | first2 = T. | title = Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block | journal = Pharmacol Toxicol | volume = 90 | issue = 5 | pages = 246–53 |date=May 2002 | doi =  10.1034/j.1600-0773.2002.900504.x| pmid = 12076305 }}</ref>
